Oramed Pharmaceuticals Inc. — Director's Dealing 2022

Feb 15, 2022

SEC Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RAKIN KEVIN					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
					ORMP ]							X	Director		10% Owner
(Last)	(First) 36 CHURCH LANE		3. Date of Earliest Transaction (Month/Day/Year) 02/11/2022							below)	Officer (give title		Other (specify below)
4. If Amendment, Date of Original Filed (Month/Day/Year) (Street) WESTPORT CT 06880 (City) (State) (Zip)										6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) Date			2. Transaction (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
							Code	V	Amount	(A) or Price (D)			Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock 02/11/2022							G	V	5,000	D	\$0	(1)	47,004		D
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4.	5. Number Transaction of Code (Instr. Derivative			6. Date Exercisable and 7. Title and Expiration Date Amount of (Month/Day/Year) Securities				8. Price of 9. Number of Derivative derivative Security Securities		10.	Ownership Form:	11. Nature of Indirect Beneficial

Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents a charitable donation effective February 11, 2022. This is not a market transaction, thus no price has been reported. No value was received for the donated shares.

/s/ Kevin Rakin 02/14/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.